Our top pick for
Delcath Systems, Inc is a medical devices business based in the US. Delcath Systems shares (DCTH) are listed on the NASDAQ and all prices are listed in US Dollars. Delcath Systems employs 33 staff and has a trailing 12-month revenue of around USD$1.7 million.
|Latest market close||USD$16.22|
|52-week range||USD$6.06 - USD$24|
|50-day moving average||USD$15.0934|
|200-day moving average||USD$11.8425|
|Wall St. target price||USD$19.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.838|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-11.46%|
|1 month (2020-12-17)||-0.43%|
|3 months (2020-10-15)||40.43%|
|6 months (2020-07-15)||77.27%|
|1 year (2020-01-15)||8.13%|
|2 years (2019-01-15)||5,918.55%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||3,504.44%|
|Revenue TTM||USD$1.7 million|
|Gross profit TTM||USD$861,000|
|Return on assets TTM||-66.49%|
|Return on equity TTM||0%|
|Market capitalisation||USD$98.9 million|
TTM: trailing 12 months
There are currently 181,313 Delcath Systems shares held short by investors – that's known as Delcath Systems's "short interest". This figure is 19.8% up from 151,336 last month.
There are a few different ways that this level of interest in shorting Delcath Systems shares can be evaluated.
Delcath Systems's "short interest ratio" (SIR) is the quantity of Delcath Systems shares currently shorted divided by the average quantity of Delcath Systems shares traded daily (recently around 166342.20183486). Delcath Systems's SIR currently stands at 1.09. In other words for every 100,000 Delcath Systems shares traded daily on the market, roughly 1090 shares are currently held short.
However Delcath Systems's short interest can also be evaluated against the total number of Delcath Systems shares, or, against the total number of tradable Delcath Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Delcath Systems's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Delcath Systems shares in existence, roughly 30 shares are currently held short) or 0.0351% of the tradable shares (for every 100,000 tradable Delcath Systems shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Delcath Systems.
Find out more about how you can short Delcath Systems stock.
We're not expecting Delcath Systems to pay a dividend over the next 12 months.
Delcath Systems's shares were split on a 1:700 basis on 24 December 2019. So if you had owned 700 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Delcath Systems shares – just the quantity. However, indirectly, the new 69900% higher share price could have impacted the market appetite for Delcath Systems shares which in turn could have impacted Delcath Systems's share price.
Over the last 12 months, Delcath Systems's shares have ranged in value from as little as $6.06 up to $24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Delcath Systems's is 0.7932. This would suggest that Delcath Systems's shares are less volatile than average (for this exchange).
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.